We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 28, 2020

Nivolumab vs Everolimus in Patients With Advanced RCC



Additional Info

Disclosure statements are available on the authors' profiles:

Nivolumab Versus Everolimus in Patients With Advanced Renal Cell Carcinoma: Updated Results With Long-Term Follow-Up of the Randomized, Open-Label, Phase 3 CheckMate 025 Trial
Cancer 2020 Jul 16;[EPub Ahead of Print], RJ Motzer, B Escudier, S George, HJ Hammers, S Srinivas, SS Tykodi, JA Sosman, ER Plimack, G Procopio, DF McDermott, D Castellano, TK Choueiri, F Donskov, H Gurney, S Oudard, M Richardet, K Peltola, AS Alva, M Carducci, J Wagstaff, C Chevreau, S Fukasawa, Y Tomita, TC Gauler, CK Kollmannsberger, FA Schutz, J Larkin, D Cella, MB McHenry, SS Saggi, NM Tannir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading